MRK vs RCEL
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
RCEL presents a high-risk profile characterized by a stable Piotroski F-Score (5/9) that masks severe underlying liquidity and solvency issues. The company exhibits negative shareholders' equity (Price/Book: -9.43) and a critical liquidity shortage with a current ratio of 0.57, indicating an inability to cover short-term obligations. Despite strong gross margins (82.13%) and bullish analyst targets, the fundamental trend is negative with shrinking revenue (-4.30%) and a consistent history of missing earnings estimates.
Compare Another Pair
Related Comparisons
MRK vs RCEL: Head-to-Head Comparison
This page compares Merck & Co., Inc. (MRK) and AVITA Medical, Inc. (RCEL) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.